Acadia Pharma (ACAD) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $22.09 --0%
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +12.1%
Financial Fact:
Loss from operations: -72.4M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $17 thousand versus the consensus estimate of $60 thousand.
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- AMC Entertainment prices $200M stock offering to redeem senior notes
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
